Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q3

4587.TEDINET S100PLL7
Period2022-01-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 65
MetricValuePeriodScopeSource row
Revenue¥11.2bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.2bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥9.4bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥7.8bn2021-01-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥4.9bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income−¥427m2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.2bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥4.0bn2021-01-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥3.6bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax−¥369m2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.2bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥3.8bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.8bn2021-01-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥3.5bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)−¥187m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥946m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥2.5bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.5bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥187m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥946m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥2.5bn2021-01-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥2.5bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥51.3bnat 2022-09-30Cons.Assets IFRS
Total assets¥27.0bnat 2021-12-31Cons.Assets IFRS
Total assets¥28.1bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total assets¥26.1bnat 2020-12-31dCons.Assets IFRS
Total liabilities¥26.8bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥1.7bnat 2021-12-31Cons.Liabilities IFRS
Total liabilities¥4.9bnat 2020-12-31dCons.Liabilities IFRS
Net assets / equity¥24.5bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥25.2bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥21.3bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥24.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.4bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.2bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥21.3bnat 2020-12-31dCons.Equity attributable to owners of parent IFRS
Cash & equivalents¥4.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥12.2bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥7.1bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥1.4bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥6.6bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥27.0bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.7bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥20.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥66m2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥45m2021-01-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-1.442022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.282022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥19.962021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥19.252021-01-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.132021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-1.442022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.812021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.062021-01-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.122021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio47.7%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio93.8%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio89.4%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 13
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥8m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥197m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥8m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥183m
—segment totalrevenue2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥8m
—segment totalsegment profit2022-01-01 → 2022-09-30−¥14m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 629
ItemContextValueUnit
Increase or decrease in retirement benefit asset or liability ope cf IFRSPrior1YTDDuration－JPY
Increase or decrease in retirement benefit asset or liability ope cf IFRSCurrentYTDDuration5452000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration-128667000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration-1144271000JPY
Subtotal ope cf IFRSPrior1YTDDuration9005931000JPY
Subtotal ope cf IFRSCurrentYTDDuration-888695000JPY
Interest and dividends received ope cf IFRSPrior1YTDDuration279000JPY
Interest and dividends received ope cf IFRSCurrentYTDDuration1238000JPY
Interest paid ope cf IFRSPrior1YTDDuration－JPY
Interest paid ope cf IFRSCurrentYTDDuration-101220000JPY
Income taxes paid ope cf IFRSPrior1YTDDuration-2384104000JPY
Income taxes paid ope cf IFRSCurrentYTDDuration-441013000JPY
Income taxes refund ope cf IFRSPrior1YTDDuration131000JPY
Income taxes refund ope cf IFRSCurrentYTDDuration21102000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration6622237000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration-1408588000JPY
Proceeds from sale of marketable securities inv cf IFRSPrior1YTDDuration145222000JPY
Proceeds from sale of marketable securities inv cf IFRSCurrentYTDDuration－JPY
Payments for acquisition of subsidiaries inv cf IFRSPrior1YTDDuration－JPY
Payments for acquisition of subsidiaries inv cf IFRSCurrentYTDDuration-23460335000JPY
Purchase of shares of subsidiaries and associates inv cf IFRSPrior1YTDDuration-506000000JPY
Purchase of shares of subsidiaries and associates inv cf IFRSCurrentYTDDuration－JPY
Loan advances to subsidiaries and associates inv cf IFRSPrior1YTDDuration-414097000JPY
Loan advances to subsidiaries and associates inv cf IFRSCurrentYTDDuration－JPY
Collection of loans receivable inv cf IFRSPrior1YTDDuration4681000JPY
Collection of loans receivable inv cf IFRSCurrentYTDDuration67486000JPY
Grant amount received inv cf IFRSPrior1YTDDuration136323000JPY
Grant amount received inv cf IFRSCurrentYTDDuration－JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-1054846000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-3449779000JPY
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-13857000JPY
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-110328000JPY
Other inv cf IFRSPrior1YTDDuration55000JPY
Other inv cf IFRSCurrentYTDDuration-10763000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-1702519000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-26963720000JPY
Proceeds from long term borrowings fin cf IFRSPrior1YTDDuration－JPY
Proceeds from long term borrowings fin cf IFRSCurrentYTDDuration22400000000JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration－JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-1120000000JPY
Payments of borrowing fee fin cf IFRSPrior1YTDDuration－JPY
Payments of borrowing fee fin cf IFRSCurrentYTDDuration-212800000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration－JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-141573000JPY
Proceeds from issuance of shares resulting from exercise of share acquisition rights fin cf IFRSPrior1YTDDuration44940000JPY
Proceeds from issuance of shares resulting from exercise of share acquisition rights fin cf IFRSCurrentYTDDuration－JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration-356000JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration-87000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration44583000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration20925538000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 17 of 17 passed
balance sheet identityconsolidated 2020-12-31pass
balance sheet identityconsolidated 2021-12-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass